The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to a treatment for osteosarcoma.  SOT106, developed by biopharmaceutical company SOTIO Biotech, is a next-generation antibody-drug conjugate (ADC) targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumour associated stroma.  Preclinical data has shown strong anti-tumour activity in both soft tissue and osteosarcoma models […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!